期刊
CANCERS
卷 11, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cancers11070949
关键词
PI3K-AKT-mTOR; NF kappa B; ovarian cancer; therapy
类别
资金
- Marsha Rivkin Pilot Award
- WFBMC Department of Pathology Research Pilot Funds
- [R01 CA193437]
Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-kappa light chain enhancer of activated B cells (NF kappa B) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NF kappa B pathway in ovarian cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据